Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Vadadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3, with IC50s of 1.1 and 0.39 micromolar, respectively. It stabilizes HIF-1α in mouse hepatocyte nuclear extracts and increases erythropoietin levels in mouse serum, making it a promising pharmaceutical candidate for anemia treatment in nondialysis-dependent chronic kidney disease.

1000025-07-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1000025-07-9 Structure
  • Basic information

    1. Product Name: Vadadustat
    2. Synonyms: Vadadustat;Vadadustat(AKB-6548/PG-1016548)
    3. CAS NO:1000025-07-9
    4. Molecular Formula: C14H11ClN2O4
    5. Molecular Weight: 306.70114
    6. EINECS: N/A
    7. Product Categories: API
    8. Mol File: 1000025-07-9.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 674.6±55.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.461±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
    8. Solubility: DMSO (Slightly), Methanol (Slightly)
    9. PKA: 4.09±0.40(Predicted)
    10. Stability: Hygroscopic
    11. CAS DataBase Reference: Vadadustat(CAS DataBase Reference)
    12. NIST Chemistry Reference: Vadadustat(1000025-07-9)
    13. EPA Substance Registry System: Vadadustat(1000025-07-9)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1000025-07-9(Hazardous Substances Data)

1000025-07-9 Usage

Uses

Used in Pharmaceutical Industry:
Vadadustat is used as an anemia treatment for nondialysis-dependent chronic kidney disease. It functions by stabilizing HIF-1α, which in turn increases erythropoietin levels in the serum, providing an effective treatment for anemia in this patient population.

Check Digit Verification of cas no

The CAS Registry Mumber 1000025-07-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,0,2 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1000025-07:
(9*1)+(8*0)+(7*0)+(6*0)+(5*0)+(4*2)+(3*5)+(2*0)+(1*7)=39
39 % 10 = 9
So 1000025-07-9 is a valid CAS Registry Number.

1000025-07-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name vadadustat

1.2 Other means of identification

Product number -
Other names N-[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]glycine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1000025-07-9 SDS

1000025-07-9Downstream Products

1000025-07-9Relevant articles and documents

MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT

-

, (2022/01/12)

Disclosed herein are methods and processes of preparing vadadustat or a pharmaceutically acceptable salts thereof, and intermediates (e.g., a compound of Formula (I), (I-F), (II), or (IV), or a pharmaceutically acceptable salts thereof) useful for the syn

Development of a Robust and Scalable Process for the Large-Scale Preparation of Vadadustat

Lin, Biyue,Kou, Jingping,Wu, Shuming,Cai, Xuerong,Xiao, Qingbo,Li, Yinglong,Hu, Jian,Li, Jianbing,Wang, Zhongqing

, p. 960 - 968 (2021/04/05)

A novel and scalable process is developed for the industrial synthesis of vadadustat. The four-step process is one step shorter compared to the reported routes with an increase in total yield to 49.1%. Detailed optimizations furnish vadadustat with a purity of >99.5% through cross-coupling, aromatic substitution and nitrile hydrolysis, amidation, and ester-ether deprotection. The process is also robust and was demonstrated in a kilogram laboratory. Meanwhile, the corresponding impurity profile was thus studied in detail and well documented.

Preparation method of valduxostat and intermediate thereof

-

Paragraph 0067-0076, (2021/09/15)

The invention relates to a preparation method of valduxostat and an intermediate thereof, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: taking 3-chloro-5-(3-chlorphenyl)-2-cyanopyridine as a starting material, carrying out hydrolysis reaction, and then carrying out condensation reaction to obtain a compound, namely the intermediate; and further reacting the intermediate compound to obtain vadadustat. The method has the advantages of short route, simple and easily available raw materials, low cost and mild reaction conditions, and is suitable for industrial large-scale production.

NOVEL CRYSTALLINE COMPOUND OF VADADUSTAT

-

Page/Page column 11, (2021/12/31)

The present invention relates to a novel crystalline compound of Vadadustat, to processes for its preparation, to pharmaceutical compositions containing it and to its use in therapy.

Preparation method of pyridine cyclic compound

-

Paragraph 0041; 0054-0057; 0064-0065, (2020/06/16)

The invention provides a preparation method of a pyridine cyclic compound, and belongs to the field of pharmaceutical chemicals. The method comprises the steps: mixing 3,5-dihydroxypicolinic acid, concentrated sulfuric acid and an alcohol solvent, and performing esterification reaction to obtain 3,5-dihydroxypicolinic acid methyl ester; then sequentially carrying out protection group feeding and ammoniation to obtain {[5-(3-chlorphenyl)-3-hydroxypyridin-2-yl]amino}acetic acid. The product produced by the method has the characteristics of high purity, high yield, low cost, simple operation andstable process.

Preparation method and application of phenylpyridine compound

-

Paragraph 0039; 0059-0066, (2020/07/28)

The invention relates to a preparation method and application of a phenylpyridine compound, and belongs to the field of pharmaceutical chemicals. The method disclosed by the invention comprises the following steps: mixing 5-(3-chlorphenyl)-2-cyano-3-chloropyridine, alkali and an organic solvent to obtain 5-(3-chlorphenyl)-3-hydroxyl-pyridine formamide; and then sequentially carrying out a reactionwith sulfuric acid and glycine so as to obtain {[5-(3-chlorphenyl)-3-hydroxypyridine-2-yl] amino} acetic acid. The product produced by the method is high in purity, high in yield, low in process cost, simple to operate and stable in process.

Preparation method and application of picolinamide

-

, (2020/07/12)

The invention provides a preparation method of a picolinamide compound, and belongs to the field of pharmaceutical and chemical industry. According to the preparation method, 3,5-dihydroxypicolinic acid methyl ester, hydroxylamine hydrochloride, an alkali

Preparation method of vadadustat

-

Paragraph 0047; 0060-0065, (2020/04/02)

The invention provides a preparation method of vadadustat, and belongs to the field of pharmaceutical chemical industry. The method comprises the following steps: mixing 3,5-dichloro-2-picolinic acid,methanol and sulfuric acid at a certain temperature, and carrying out a reaction to obtain 3,5-dichloro-2-picolinic acid methyl ester; adding 3-chlorophenylboronic acid, and carrying out a catalyticreaction to obtain 5-(3-chlorphenyl)-3-chloropyridine-methyl formate; and adding glycine into the 5-(3-chlorphenyl)-3-chloropyridine-methyl formate, and carrying out a reaction to obtain the 5-(3-chlorphenyl)-3-chloropyridine-methyl formate. The method has the characteristics of high product purity, high yield, low cost, simple operation and stable process.

Preparation method of vardoxostat intermediate

-

Paragraph 0057-0059, (2020/11/12)

The invention relates to a preparation method of a vardoxostat intermediate, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: taking 3-methoxy-5-(3-chlorphenyl)-2-cyanopyridine as a starting material, carrying out hydrolysis reaction and condensation reaction to obtain an intermediate of a compound; the intermediate compound can be subjected toa further reaction to obtain vadustat (vardoxostat); the method has the advantages of short route, simple and accessible raw materials, lower cost and mild reaction conditions, and is suitable for industrial large-scale production.

PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID

-

Paragraph 0071, (2019/11/28)

Disclosed herein are methods and processes of preparing vadadustat and pharmaceutically acceptable salts thereof, and intermediates of formula (I) and their salts useful for the synthesis of vadadustat.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1000025-07-9